201 related articles for article (PubMed ID: 30669833)
1. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA.
Haga Y; Uemura M; Baba S; Inamura K; Takeuchi K; Nonomura N; Ueda K
Anal Chem; 2019 Feb; 91(3):2247-2254. PubMed ID: 30669833
[TBL] [Abstract][Full Text] [Related]
2. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.
Llop E; Ferrer-Batallé M; Barrabés S; Guerrero PE; Ramírez M; Saldova R; Rudd PM; Aleixandre RN; Comet J; de Llorens R; Peracaula R
Theranostics; 2016; 6(8):1190-204. PubMed ID: 27279911
[TBL] [Abstract][Full Text] [Related]
3. LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer.
Inoue T; Kaneko T; Muramatsu S; Kimura H; Yoshino T; Goto T; Sawada A; Akamatsu S; Kobayashi T; Yamasaki T; Kaya T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e28-e36. PubMed ID: 31711843
[TBL] [Abstract][Full Text] [Related]
4. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
[No Abstract] [Full Text] [Related]
5. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
[TBL] [Abstract][Full Text] [Related]
6. Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.
Li QK; Chen L; Ao MH; Chiu JH; Zhang Z; Zhang H; Chan DW
Theranostics; 2015; 5(3):267-76. PubMed ID: 25553114
[TBL] [Abstract][Full Text] [Related]
7. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
[TBL] [Abstract][Full Text] [Related]
8. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
Xu L; Hu X; Zhu Y; Lu J; Xu Y; Wang G; Guo J
Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
[TBL] [Abstract][Full Text] [Related]
9. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
10. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.
Yoneyama T; Ohyama C; Hatakeyama S; Narita S; Habuchi T; Koie T; Mori K; Hidari KI; Yamaguchi M; Suzuki T; Tobisawa Y
Biochem Biophys Res Commun; 2014 Jun; 448(4):390-6. PubMed ID: 24814705
[TBL] [Abstract][Full Text] [Related]
11. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
12. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
13. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
[TBL] [Abstract][Full Text] [Related]
14. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of the LacdiNAc-glycosylated prostate-specific antigen assay for prostate cancer detection.
Yoneyama T; Tobisawa Y; Kaneko T; Kaya T; Hatakeyama S; Mori K; Sutoh Yoneyama M; Okubo T; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Ito A; Koie T; Suda Y; Gardiner RA; Ohyama C
Cancer Sci; 2019 Aug; 110(8):2573-2589. PubMed ID: 31145522
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of the main PSA glycoforms in aggressive prostate cancer.
Gratacós-Mulleras A; Duran A; Asadi Shehni A; Ferrer-Batallé M; Ramírez M; Comet J; de Llorens R; Saldova R; Llop E; Peracaula R
Sci Rep; 2020 Nov; 10(1):18974. PubMed ID: 33149259
[TBL] [Abstract][Full Text] [Related]
17. Lectin Affinity Chromatography for the Discovery of Novel Cancer Glycobiomarkers: A Case Study with PSA Glycoforms and Prostate Cancer.
Llop E; Peracaula R
Methods Mol Biol; 2022; 2370():301-313. PubMed ID: 34611876
[TBL] [Abstract][Full Text] [Related]
18. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of molecular species of prostate-specific antigen complexed with immunoglobulin M in prostate cancer and benign prostatic hyperplasia.
Goč S; Janković M
Dis Markers; 2013; 35(6):847-55. PubMed ID: 24367138
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
